Down Syndrome (Trisomy 21) neurons possess an extra copy of chromosome 21, leading to gene dosage effects that significantly impact brain development and function. Individuals with Down Syndrome have a dramatically increased risk of developing Alzheimer's disease by middle age, with neuropathological features appearing as early as the third decade of life[1]. [1:1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Genetic Disorder Neurons | [4]
| Chromosome | Trisomy 21 (3 copies of chromosome 21) | [5]
| Prevalence | ~1 in 700 live births | [6]
| APP Copy Number | 3 copies (gene dosage effect) |
| AD Risk by Age 60 | >50% |
The triplication of chromosome 21 results in overexpression of approximately 300-400 genes. Key genes relevant to neurodegeneration include:
The APP gene dosage effect is central to the pathogenesis of Alzheimer's disease in Down Syndrome:
Individuals with Down Syndrome exhibit characteristic brain morphologies:
Trisomy 21 affects neuronal development through several mechanisms:
The brains of individuals with Down Syndrome who develop dementia show classic AD pathology:
Cerebrospinal fluid and imaging biomarkers in DS-AD:
| Biomarker | Change | Diagnostic Utility |
|---|---|---|
| Aβ42 | Decreased | High |
| Total Tau | Increased | Moderate |
| Phospho-tau | Increased | High |
| Amyloid PET | Positive | High |
The APP dosage effect makes it a prime therapeutic target:
Several trials are underway targeting AD in Down Syndrome:
Transgenic models mimicking DS neurobiology:
Current research focuses on:
](/diseases/down-syndrome-and-alzheimers-disease
--amyloid-precursor-protein-app-gene
--amyloid-beta-aβ-protein
--trisomy-21
--intellectual-disability
--early-onset-alzheimers-disease)## External Links
The study of Down Syndrome (Trisomy 21) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
. Wiseman FK, et al. Trisomy 21 causes changes in the brain that confer vulnerability to Alzheimer's disease. Brain. 2015;138(Pt 8):2356-2371. 2015. ↩︎ ↩︎
. Lott IT, Dierssen M. Alzheimer's disease and Down syndrome: from meiosis to neurodegeneration. Nat Rev Neurosci. 2010;11(12):823-833. 2010. ↩︎
. Salehi A, et al. APP, APLPs, and Down syndrome: the role of APP. J Mol Neurosci. 2006;29(3):265-278. 2006. ↩︎
. Matsuda K, et al. APP mouse models: a platform for Alzheimer's disease drug discovery. Acta Neuropathol Commun. 2023;11(1):52. 2023. ↩︎
. Head E, et al. Cerebrovascular pathology in Down syndrome and Alzheimer disease. Acta Neuropathol Commun. 2017;5(1):93. 2017. ↩︎
. Ivy GO, et al. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2008;14(4):259-268. 2008. ↩︎